Refine
Year of publication
Document Type
- Article (32)
- Preprint (5)
- Review (2)
- Report (1)
- Working Paper (1)
Has Fulltext
- yes (41)
Is part of the Bibliography
- no (41)
Keywords
- Acuris (2)
- Decorin (2)
- Gene expression (2)
- IR-A (2)
- Pre-analytics (2)
- Proliferation (2)
- Signaling (2)
- ACURATE neo (1)
- ALL (1)
- AML (1)
Institute
- Medizin (24)
- Physik (9)
- Institut für Ökologie, Evolution und Diversität (2)
- Neuere Philologien (2)
- Sonderforschungsbereiche / Forschungskollegs (2)
- Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit (ZAFES) (2)
- Biowissenschaften (1)
- Center for Financial Studies (CFS) (1)
- Geographie (1)
- House of Finance (HoF) (1)
Purpose: The role of obesity in glioblastoma remains unclear, as previous analyses have reported contradicting results. Here, we evaluate the prognostic impact of obesity in two trial populations; CeTeG/NOA-09 (n = 129) for MGMT methylated glioblastoma patients comparing temozolomide (TMZ) to lomustine/TMZ, and GLARIUS (n = 170) for MGMT unmethylated glioblastoma patients comparing TMZ to bevacizumab/irinotecan, both in addition to surgery and radiotherapy.
Methods: The impact of obesity (BMI ≥ 30 kg/m2) on overall survival (OS) and progression-free survival (PFS) was investigated with Kaplan–Meier analysis and log-rank tests. A multivariable Cox regression analysis was performed including known prognostic factors as covariables.
Results: Overall, 22.6% of patients (67 of 297) were obese. Obesity was associated with shorter survival in patients with MGMT methylated glioblastoma (median OS 22.9 (95% CI 17.7–30.8) vs. 43.2 (32.5–54.4) months for obese and non-obese patients respectively, p = 0.001), but not in MGMT unmethylated glioblastoma (median OS 17.1 (15.8–18.9) vs 17.6 (14.7–20.8) months, p = 0.26). The prognostic impact of obesity in MGMT methylated glioblastoma was confirmed in a multivariable Cox regression (adjusted odds ratio: 2.57 (95% CI 1.53–4.31), p < 0.001) adjusted for age, sex, extent of resection, baseline steroids, Karnofsky performance score, and treatment arm.
Conclusion: Obesity was associated with shorter survival in MGMT methylated, but not in MGMT unmethylated glioblastoma patients.